Human Reproduction Update Advance Access originally published online on March 24, 2005
Human Reproduction Update 2005 11(3):215-228; doi:10.1093/humupd/dmi003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The role of paf in embryo physiology
Human Reproduction Unit, Department of Physiology, University of Sydney, Royal North Shore Hospital, St Leonards, NSW, 2065, Australia
Email: chriso{at}med.usyd.edu.au
 |
Abstract |
|---|
TOP
Abstract
IntroductionEmbryo-derived paf (1-o-alkyl-2-acetyl-sn-gylcero-3-phosphocholine) is produced by de novo synthesis. This synthesis commences soon after fertilization and persists throughout the preimplantation phase. Paf is produced and released by the embryos of all mammalian species studied to date. Its release from the embryo involves binding to extracellular albumin in a manner that protects paf from enzymatic degradation. Released paf causes a range of alterations in maternal physiology, including platelet activation, changes in oviductal, endometrial and maternal immune function. Paf also acts in an autocrine fashion as a trophic/survival factor for the early embryo. In vitro, supplementation of culture media with paf improves embryo development. Embryo-derived paf's autocrine actions are transduced by 1-o-phosphatidylinositol-3-kinase, which induces characteristic calcium transients within the early embryo. The calcium transients require both the influx of external calcium and release of inositol trisphosphate-dependent internal calcium stores. Buffering these transients compromised embryo development in a manner that was reversed by exogenous paf. Assisted reproductive technologies compromise the production of paf by some embryos and retard the expression of the paf receptor. This deprivation of paf's action is one of the factors limiting the survivability of embryos produced by assisted reproductive technologies. Paf is one of several autocrine and paracrine trophic/survival factors that act on the early embryo. These factors probably act cooperatively and may, to some degree, be mutually redundant. As the earliest-released and the best-described embryotrophin, paf provides an important exemplar for understanding the role of ligand-mediated trophic support of the early embryo.
Key words: paf / zygote / blastocyst / embryo / fertilization in vitro / signal transduction
|
Introduction |
|---|
It is 20 years since the first report (O'Neill and Saunders, 1984
) of the release by the human embryo of a soluble factor that caused blood platelet (thrombocyte) activation. This was subsequently shown to be mediated by a potent ether phospholipid, 1-o-alkyl-2-acetyl-sn-gylcero-3-phosphocholine (paf) (O'Neill, 1985b; Collier et al., 1988). The released paf causes changes to a range of maternal reproductive tract functions. Importantly, it also acts back on receptors expressed by the embryo to complete an autocrine trophic loop. Paf is also synthesized and released by many other cell types. An equally diverse range of cells are shown to be biologically responsive to paf. While not a universal mediator, paf is certainly used in an extraordinary range of physiological and pathological settings. Since paf is made by and acts upon the zygote, it is perhaps not surprising that such a diverse range of cells within the body should subsequently be responsive to the mediator. Given its diversity of action, the original name of platelet-activating factor is no longer suitable or relevant. Rather, the term paf should solely be used. Paf should refer to the biochemical entity 1-o-alkyl-2-acetyl-sn-gylcero-3-phosphocholine. It should not refer to the biological activity since many agents have platelet-activating functions. The term platelet-activating factor should now fade from use.
Paf was the first mediator released by the preimplantation embryo to be identified (O'Neill, 1985a,b). It was subsequently shown that paf stimulated embryo metabolism (Ryan et al., 1989), cell-cycle progression (Roberts et al., 1993) and embryo viability (Spinks and O'Neill, 1988; Ryan et al., 1990b; Spinks et al., 1990) providing evidence for an autocrine loop in the early embryo. Insulin (Wales et al., 1985) also exerts trophic effects on the early embryo, the early embryo expresses a functional receptor for insulin (Harvey and Kaye, 1988; Heyner et al., 1989), but not insulin itself, suggesting that potential endocrine stimulation of embryo development also occurred. The possibility that a range of trophic factors may act on the early embryo was suggested by the detection of mRNA for a range of peptide growth factor ligands and their corresponding receptors (Rappolee et al., 1988). Since these observations, many putative autocrine, paracrine and endocrine factors have been implicated in supporting preimplantation embryo development (Kane et al., 1997; Kaye, 1997; Hardy and Spanos, 2002).
For most of these putative autocrine embryonic trophic factors there is a dearth of information on the nature of their action and the nature of the embryos' response to them. In recent years some information on the nature of paf's signal transduction within the embryo has become available, and to date paf's actions on the early embryo are the best described of the putative embryotrophins. Since paf seems to be one of the first of these factors to be produced and act on the embryo, it seems a suitable exemplar for studies of the role and mode of action of the embryotrophins.
Paf is also produced by a range of other reproductive tissues, including the endometrium, sperm, the ovary and the fetus. This review will primarily consider the actions of embryo-derived paf during the preimplantation stage of development.
|
Discovery of embryo-derived paf |
|---|
Paf was first identified as an agent released from sensitized basophils as a consequence of antigenic stimulation (Benveniste et al., 1972
). It was proposed as one of the early onset mediators of hypersensitivity responses. Its biochemical identification (Demopoulos et al., 1979) was soon followed by evidence that it was the same entity as a mediator with renal antihypertensive activity (Wykle et al., 1980). Its identity as an ether phospholipid was surprising since this class of lipids, allthough well described as minor but important structural components of membranes, was not considered at the time to be biologically active.
Its release by the early embryo was detected by the observation of a significant thrombocytopenia soon after conception (O'Neill, 1985a,c). This occurred in several strains of mice and was shown to be unequivocally a consequence of fertilization (rather than insemination, ovulation or any of the endocrine events associated with fertilization) (O'Neill 1985a,c). The thrombocytopenia could also be induced by injection of embryo-conditioned culture media into mice. The chemical identity of the active agent was confirmed by structural analysis (O'Neill, 1985b), chromatography (Ammit et al., 1992), metabolic studies (Wells and O'Neill, 1992), mass spectrometry (Kodama et al., 1989) and immunological assays (Ammit and O'Neill, 1991). The release of paf by embryos has been confirmed in the human (Collier et al., 1990; Vereecken et al., 1990; Nakatsuka et al., 1992), mouse (Kodama et al., 1989; Ripps et al., 1993; Suzuki et al., 1995), sheep (Battye et al., 1991), rabbit (Minhas et al., 1993), and hamster (Velasquez et al., 1995). Paf release by the early embryo may occur in most mammalian species. A more extensive phylogenetic study has not been completed and is warranted.
As a consequence of embryo-derived paf release, platelet activation occurs within the microvasculature of the oviduct (Stein and O'Neill, 1994). It is likely that the resulting activated platelets are trapped by the reticuloendothelial system and hence are lost from circulation in early pregnancy-associated thrombocytopenia. This occurs in mice (O'Neill, 1985c), bovine (Kojima et al., 1996a), hamster (Velasquez et al., 1995) and rabbit (Kojima et al., 1996b). In the human there is a mixed picture, with thrombocytopenia in some cases and thrombocytosis in others (O'Neill et al., 1988; Yeung et al., 1992). The excess production of platelets in thrombocytosis may well be a reflex to the acute consumption of platelets that occurs following fertilization (O'Neill et al., 1988).
Paf also initiates a change in the function of the maternal immune system early in pregnancy, manifested as a modification of T-lymphocyte rosette formation (Orozco et al., 1986; Sueoka et al., 1988). The full physiological significance of this change in T-lymphocyte function is not known, but it has been interpreted by some as evidence of maternal immunosuppression (Morton et al., 1976).
The release of a mediator from the single cell zygote capable of causing such extensive changes to maternal physiology suggests that it was a molecule of extraordinary potency. This proved to be the case, with paf activity in some bioassays being in the range 10–12–10–14 mol/l. The fact that paf is a phospholipid offered the possibility that its synthesis and release may occur without the requirement for new transcription from the embryonic genome. These observations make paf an attractive candidate for important signalling events in the initiation of early pregnancy.
|
The biosynthesis of embryo-derived paf |
|---|
Embryos have high levels of paf release, ranging from 1 to 100 s of ng paf per embryo per 24 h (Ammit and O'Neill, 1991
; Roudebush et al., 2002a). This output suggests that the release is likely to be the result of new synthesis rather than release of preformed stores. Paf's biosynthetic pathway in somatic cells has been well described (for review see Snyder, 1995). Pulse-chase studies showed that several radiolabelled precursors were incorporated in the paf released by the embryo (Wells and O'Neill, 1992). Importantly this occurred not only for immediate precursors such as lysopaf but also for more basic components such as long chain alcohols (hexadecanol and octadecanol) and alkylacetylglycerol. Radiolabelled simple substrates such as lactate, pyruvate and glucose were also incorporated into released paf. These pulse-chase studies showed that the early embryo produced and released paf and that synthesis occurred de novo from basic substrates. The biosynthetic pathways inferred from these studies are shown in Figure 1.
|
The incorporation of the long chain alcohols (hexadecanol and octadecanol) by formation of an ether linkage occurs within the peroxisome of cells. The reaction utilizes the enzyme alkyl-dihydroxyacetone phosphate synthase (EC 2.5.1.26 [EC] ) (van den Bosch et al., 1993
). Thus, peroxisomal status has particular importance within cells synthesizing paf (and other ether lipids) de novo. Currently, there is little knowledge of peroxisomal status and biogenesis within the early embryo. Mouse embryos produce paf using either hexadecanol or octadecanol. There is considerable heterogeneity in the amounts of each form of embryo-derived paf synthesized. Overall, there is more hexadecyl-paf than octadecyl-paf production found (Ammit et al., 1992). In many cultures embryos exclusively produce hexadecyl-paf, whereas this was uncommon for octadecyl-paf. This pattern of biosynthesis may be biologically relevant since it is reported that for mouse embryos hexadecyl-paf exerted trophic actions on the embryo whereas octadecyl-paf was inert (Stoddart et al., 2001). The results also suggest that an understanding of long chain alcohol biosynthesis within the early embryo has important developmental implications.
A penultimate step in embryo-derived paf biosynthesis produces lysopaf and arachidonic acid. The final reaction converts lysopaf to paf via acetylation (Figure 1). The regulation of embryo-derived paf's biosynthesis may be at the final steps of its synthesis, since activity of acetyl-coenzyme A:lysopaf acetyltransferase (EC 2.3.1.67
[EC]
) sharply increased at the time that paf synthesis and release occurs (zygote) and peaked at the 2-cell stage (in mouse) (Wells and O'Neill, 1994). By contrast, a critical enzyme in the de novo synthesis of paf (cytidine:alkylacetylgylcerol cholinephosphotransferase) showed relatively modest changes in activity during early development (Wells and O'Neill, 1994).
|
Paf metabolism |
|---|
The deacetylation of paf creates lysopaf. Lysopaf is biologically inert in paf bioassays. A special class of phospholipase A2 (PLA2) (groups VII and VIII) deacetylates paf (Tjoelker et al., 1995
). This PLA2 activity is commonly referred to as paf:acetylhydrolase (pafah, EC 3.1.1.47
[EC]
). It is thought to have specific roles in modulating paf bioavailability and limiting its half-life (the enzyme activity also has a role in detoxifying oxidized phospholipids) (Prescott et al., 2000). The ubiquitous nature of these metabolic enzymes for paf has led to the generally accepted concept that released paf does not accumulate to a sufficient concentration nor persist for long enough to act as other than a local autocrine or paracrine mediator.
Pafah takes several molecular forms: a plasma (hepatic) form and several intracellular forms (for review see Prescott et al., 2000). A pafah activity was detected within the 2-cell embryo, although it was not biochemically identified (Wells and O'Neill, 1994). Pafah activity was also present within the uterus during the preimplantation stage of pregnancy. Its activity changed markedly throughout the reproductive cycle. Activity was at a minimum in the endometrium and uterine luminal fluid during the preimplantation phase of pregnancy (O'Neill, 1995a). Pafah activity was reciprocally regulated by estradiol and progesterone (Chami and O'Neill, 2001). The dominant pafah activity within the endometrium and the uterine lumen during early pregnancy in the mouse had the biochemical characteristics of the plasma form of the enzyme (Chami and O'Neill, 2001). Thus, at a time when the embryo is producing and releasing paf, the sex steroids act on the uterus to reduce pafah activity.
In vitro, embryo-derived paf was not degraded by serum pafah, yet exogenous paf added to the same media was readily degraded (Ammit and O'Neill, 1997b,c). Furthermore, embryo-derived paf was readily degraded by pafah following its extraction and preparation as an aqueous solution. The resistance of embryo-derived paf to hydrolysis by pafah was a consequence of the nature of its binding to albumin (Ammit and O'Neill, 1997b,c).
The combined effects of low pafah activity in the uterus and the resistance of embryo-derived paf to pafah suggest that embryo-derived paf released by the embryo is capable of accumulating to biologically significant quantities in vivo.
|
Paf-binding proteins |
|---|
Embryo-derived paf displayed differences in biochemical behaviour compared with synthetic paf added to culture media (Ammit and O'Neill, 1997b
,c). This occurred despite unequivocal evidence that both sources of paf had the same chemical identity. Embryo-derived paf was not detected using a direct assay of embryo-conditioned media (with either a bioassay or immunoassay). Successful assay of embryo-derived paf required full organic extraction prior to assay. By contrast, synthetic paf added to such medium was readily measured by direct assay, as was embryo-derived paf following its organic extraction from media and re-addition to equivalent media (Ammit and O'Neill, 1997c). Synthetic paf was detected by direct assay following incubation with media for periods of 1–24 h. Furthermore, unextracted embryo-derived paf was resistant to pafah while synthetic paf added to the same media was rapidly metabolized. These differences in biological and biochemical behaviour of embryo-derived paf were a consequence of a unique form of binding of paf to albumin upon its release from the embryo. This form of binding does not occur when exogenous paf is added to media containing albumin (Ammit and O'Neill, 1997b,c).
Limited proteolytic digestion of albumin from embryo-conditioned media showed that embryo-derived paf was associated with a region of albumin located between amino acids 240 and 386 (full length 583) (Ammit and O'Neill, 1997c). By contrast, synthetic paf was largely absent from this region. This segment of albumin contains a hydrophobic core which can provide a binding region for hydrophobic molecules (Brown and Shockley, 1982; Brodersen et al., 1990; Ammit and O'Neill, 1997c). The secondary and tertiary structure of albumin is highly dependent upon the presence of 17 interchain disulphide bonds that link 34 (of the available 35) cysteine residues. Albumin in medium that was exposed to embryos expressed more reactive thiol residues than untreated medium and was more readily reduced by dithiothreitol. Thus embryo-dependent conformational changes to albumin, involving cysteine–cysteine disulphide bonds, occurred in conjunction with the loading of embryo-derived paf into a solvent-protected site (Ammit and O'Neill, 1997c).
Breaking the disulphide bonds within albumin was required to remove the solvent-protected status of cell-derived paf and suggests that some form of disulphide isomerization is required for paf's ‘release’ from the cell and binding to albumin (Ammit and O'Neill, 1997c).
It is clear that this special form of binding of embryo-derived paf to albumin is not required for paf's trophic action on the embryo, since these actions can be readily mimicked by synthetic paf added to culture media (Ryan et al., 1990b; Emerson et al., 2000). Rather, it seems likely that the special nature of embryo-derived paf's binding to albumin upon its release ensures that the paf released is not immediately inactivated by pafah, but can accumulate to biologically relevant concentrations. The relationship between paf release and action is illustrated in Figure 2.
|
|
The release of paf |
|---|
Whereas some cell types appear to retain most of the paf they synthesize (Stewart and Phillips, 1989
), other cells, including those of the preimplantation embryo, release much of their paf as a soluble mediator. There is currently a poor understanding of the nature of the release of paf by cells and there is no satisfactory explanation of why some cells release paf while others seem to primarily retain it. No convincing set of data for an intracellular role for paf is available. One possible action for retained paf is for intercellular signalling with paf acting as a juxtacrine mediator (Zimmerman et al., 1993).
Following synthesis within the intracellular organelles, paf is moved to the inner leaf of the plasma membrane (possibly mediated by transfer proteins) (Banks et al., 1988). Release of paf requires its transbilayer movement to the outer leaf of the plasma membrane. In some cells this transfer is facilitated by loss of membrane phospholipid asymmetry, possibly under the regulation of cellular transglutaminase (Bratton et al., 1991) and/or the actions of P-glycoprotein (Ernest and Bello-Reuss, 1999; Raggers et al., 2001). Upon translocation to the outer membrane, paf is available for release. The ether-linked alcohol at C1 and acetyl group at C2 causes paf to behave differently than esterified membrane lipids (Kantar et al., 1991). It is less hydrophobic than many membrane lipids (Kramp et al., 1984; Huang et al., 1986) and it is therefore likely that its release from the membrane is energetically favoured in the presence of hydrophilic acceptor molecules.
The amount of paf released by the 2-cell mouse embryo is dependent upon the extracellular albumin concentration, with the amount of paf released increasing as the albumin concentration increases (O'Neill, 1997). The albumin dependence of paf release has been demonstrated for other cell types (Benveniste et al., 1972; Ludwig et al., 1985) and it is likely that extracellular albumin acts as a general ‘acceptor’ for paf.
Embryo-derived paf induces transient increases in the intracellular calcium concentration ([Ca2+]i) within the early embryo. This action requires the presence of extracellular albumin and is inhibited by prior brief exposure of embryos to recombinant pafah or paf receptor (pafr) inhibitors (Emerson et al., 2000). This shows that while paf was present on the embryo's membrane it was susceptible to hydrolysis by pafah, but upon release to its protected site in albumin it is stable (Ammit and O'Neill, 1997c). These results have been interpreted as evidence that the autocrine action of paf requires its movement to the outer leaf of the plasma membrane of the early embryo and that its release and activity requires the action of an external acceptor molecule in the form of albumin. The carrier in turn protects paf from enzymatic degradation and donates it back to a high-affinity paf receptor on the embryo, creating an autocrine loop (Figure 2).
|
The paf receptor (pafr) |
|---|
To date, one pafr has been identified and subjected to molecular cloning. A functional pafr was first identified in a guinea-pig lung cDNA library (Honda et al., 1991
), and homologous genes have since been found in many species including the human, rat and mouse (for review see Ishii et al., 2002). The human pafr gene generates two different mRNA species, and the expression of these is under the regulation of distinct promoters (Ishii et al., 2002). The gene has an intronless open reading frame. The human gene is localized to chromosome 1 and the mouse to the D2.2 band of chromosome 4. The human receptor is a single protein composed of 342 amino acids; the mouse is one amino acid smaller. The receptor is expressed in the spermatozoon (Wu et al., 2001) and the early embryo (Roudebush et al., 1997; Stojanov and O'Neill, 1999).
The receptor belongs to the G-protein-coupled receptor family, shows wide tissue distribution and seems to account for many of the reported actions of paf (Ishii et al., 1997, 2002). Transgenic over-expression of the receptor (pafr-tg) leads to variable levels of expression within tissues. Although highly expressed in some tissues, it was barely detectable in the uterus or testis. However, mating of pafr-tg animals with wild-type partners resulted in a lower than expected penetrance of the transgene (transgenic:wildtype 1:10 for transgenic mothers and 1:2.3 for transgenic fathers) (Ishii et al., 1997). Interestingly, the litter size was reduced and the extent of this reduction corresponded to the decrease of the transgene penetrance. This implies that the reduced transgene penetrance was due to compromised survival of gametes or embryos that carried the transgene. It is yet to be defined how this is manifested. It is noteworthy that the dose–response of paf's beneficial effects on the embryo is a narrow quadratic curve; even small increments above the optimal paf concentration results in reduced embryo viability (Ryan et al., 1990a). The particularly poor transmission of the pafr-tg from female parents may imply an adverse interaction between pafr over-expression in females and the gametes/embryo. One interpretation of this model is that excessive paf signalling is detrimental to the successful establishment of pregnancy.
Interestingly, pafr-null mice were fertile following normal mating (Ishii et al., 1998), but when these mice were mated by IVF there was a marked reduction in fertilization rates compared with wild types (Wu et al., 2001). This observation is consistent with the many reports that paf is an important requirement for sperm function in vitro (Kumar et al., 1988; Baldi et al., 1993; Roudebush et al., 1993; Fukuda et al., 1994; Wu et al., 2001; Yan et al., 2003). It was also noted that pafr–/– embryos cultured in vitro developed poorly compared to pafr+/+ embryos (Lu et al., 2004). The poor development in vitro compared with that in vivo argues that paf's action on gametes and embryos occurs in concert with other trophic factors. In vivo the absence of paf signalling may be compensated by the other factors of maternal origin, whereas these would be limiting in the defined in vitro system (Wu et al., 2001; Lu et al., 2004). It is noteworthy, however, that while paf antagonists can block embryo development in vitro, a higher concentration than expected was required to achieve this effect (Emerson et al., 2000). Furthermore, paf antagonists appear to act as partial agonists (inverse agonists) rather than true antagonists in vivo. The modest reproductive phenotype of pafr–/– mice, and the apparent inverse agonism of paf antagonists on embryos (but not somatic cells), raise the possibility that the G-protein-coupled pafr may not be the sole receptor involved in transducing paf's actions in the early embryo.
There are several lines of evidence for alternative receptors, yet to date there is no conclusive evidence for their existence. One striking candidate is the type I intracellular form of pafah. Type I pafah (pafah I) forms a complex consisting of two catalytic subunits (either hetero- or homodimers of 
1 or 2 subunits) and a regulatory (ß) subunit (Watanabe et al., 1998). The regulatory subunit is homologous with the LIS1 gene. Structural analysis shows that this complex forms a G-protein-like structure (Ho et al., 1997). Pafah I 2 homodimers have anti-apoptotic functions (Bonin et al., 2004). Some paf antagonists can block cellular pafah activity (O'Neill et al., 1991) and can suppress pafah I 1 expression, hence favouring 2 homodimer formation (Bonin et al., 2004). Genetic disruption of pafah I causes early embryo lethality (Reiner et al., 1993; Hirotsune et al., 1998), due to failed proliferation of cells within the early embryo and aberrant trophoblast formation (Cahana et al., 2003). Its absence also causes failure of spermatogenesis due to apoptosis of the male germ cells (Yan et al., 2003). It has been speculated that paf (or related lipids) may regulate pafah activity in a manner analogous to the regulation of G-proteins by GTP, and thus provide a new signalling mechanism. However, strict functional proof of such a mechanism is awaited.
|
Paf in the female reproductive tract |
|---|
The female reproductive tract produces a significant amount of paf (Yasuda et al., 1986
; Angle et al., 1988; Kudolo and Harper, 1995; Chami et al., 1999) and a question that is commonly raised is whether the paf derived from the embryo and reproductive tract have different roles. Several differences are noteworthy. The production of paf by the uterus is steroid dependent and occurs in both conception and non-conception cycles (Angle et al., 1988; Chami et al., 1999; Chami and O'Neill, 2001), yet paf-induced early pregnancy-associated thrombocytopenia in mice only occurs in conception cycles or following embryo transfer (O'Neill, 1985c). This suggests that paf produced by the endometrium does not accumulate to a sufficient concentration (or is not released) capable of inducing platelet activation. The amount of paf released by the endometrium is small, and little of this paf is detected within the uterine lumen (Angle et al., 1988; Chami and O'Neill, 2001). The paf released from the endometrium is highly labile; it does not bind to albumin in a manner that protects it from hydrolysis by pafah (Chami et al., 1999). Currently, there is no definitive evidence that endometrial paf acts on the embryo.
Receptors for paf are located in the oviduct of hamsters (Velasquez et al., 2001), mice (Lash and Legge, 2001) and cows (Tiemann et al., 2001b). In the hamster, embryos migrate down the oviduct at a faster rate than unfertilized oocytes, suggesting a form of communication between the embryo and oviduct (Velasquez et al., 2001). Paf increases intracellular calcium concentrations in cultured oviduct cells (Tiemann et al., 1996). This effect was less consistently observed with human tissue (Downing et al., 1999, 2002). Physiological concentrations of paf in vitro increased ciliary beat of hamster oviduct ciliated epithelial cells, an action consistent with a role for paf in embryo migration (Hermoso et al., 2001). Paf also caused transepithelial chloride ion fluxes and changes in transepithelial electrical potential in human tubal epithelial cells (Downing et al., 1999, 2002). Embryo-derived paf also caused microvascular changes with a decrease in the cross-sectional area of small intramural blood vessels, and an apparent collapse of many subepithelial capillaries within the oviduct on day 2 of pregnancy (Stein and O'Neill, 1994). Pregnant mice also had fewer fenestrated capillaries whereas such vessels were common in pseudopregnancy. Activated platelets were only observed in the capillaries and venules of the oviduct-pregnant mice. These effects of pregnancy were reversed by a paf-receptor antagonist, suggesting that they were induced by embryo-derived paf (Stein and O'Neill, 1994). It is proposed that the local action of embryo-derived paf on the ciliated cells and smooth muscle of the oviduct together with net movement of fluid propel the embryo towards the uterus, thus accounting for preferential movement of fertilized versus unfertilized oocytes within the oviduct. The microvascular changes would undoubtedly change the oxygen tension and nutrient environment within the embryo's immediate environment. Given the early embryo's preference for a relatively hypoxic environment (Harvey et al., 2002), these changes to reproductive tract function induced by embryo-derived paf may favour development.
Paf also influences the function of the uterus (Yasuda et al., 1986). Paf is present within the uterus and its levels change under the influences of the sex steroids (Yasuda et al., 1986; Angle et al., 1988; Baldi et al., 1994; Kudolo and Harper, 1995; Chami et al., 1999). The pafr is expressed in the endometrium under the influence of the sex steroids (Ahmed et al., 1998; Chami and O'Neill, 2001; Tiemann et al., 2001a). Paf was first described as altering prostaglandins PGF and PGE release by the human endometrium in vitro (Smith and Kelly, 1988), and similar results have now been described in a range of species (Gross et al., 1990; Alecozay et al., 1991; Battye et al., 1996). Paf's effects on PG release may be mediated by nitric oxide (NO) (Ahmed et al., 1998). In the sheep, interferon (IFN) 
blocks paf-induced PGF2 release whereas oxytocin and paf have an additive effect on PGF2 release from the endometrium (Chami et al., 1999). A physiological role for endometrial paf has not been uneqivocally demonstrated. Evidence exists for several distinct roles for uterine paf at different stages of the reproductive cycle. Thus, it is implicated as a vasodilator to promote blastocyst implantation (Acker et al., 1988); as an angiogenic mediator in the regeneration of the endometrium after menses in humans (Ahmed et al., 1998); and as a mediator that acts to generate pulsatile release of PGF2 that leads to luteolysis in the non-conceptual cycle of sheep (Chami et al., 1999, 2004) (Figure 3).
|
Currently there is a body of evidence that paf produced within the female reproductive tract exerts local actions on the reproductive tract, and that embryo-derived paf also exerts actions on the reproductive tract (and has systemic effects). There is little direct evidence for an action of reproductive tract paf acting on the embryo.
|
Physiological targets of embryo-derived paf |
|---|
Given paf's many targets in early pregnancy, it was important to understand which of these functions are of most physiological relevance. Pafr antagonists were used to assess the effects of paf during early pregnancy. When administered to female rodents throughout the preimplantation phase of pregnancy, a range of paf antagonists caused a significant inhibition of the proportion of embryos that successfully implanted into the uterus (Acker et al., 1988
; Spinks and O'Neill, 1988; Ando et al., 1990a,b; Spinks et al., 1990; O'Neill, 1995b). This effect was not evident in the rabbit (Norris et al., 1994). Curiously, the inhibition of implantation in mice was generally not complete; furthermore, at high concentrations of antagonists the inhibitory effect was lost (O'Neill, 1995b). This dose-response suggests that in this model the antagonists were acting as partial agonists (inverse agonists) rather then true antagonists. This conclusion was supported by the observation that simultaneous administration of paf reversed the inhibition of embryo implantation caused by paf antagonists (Spinks and O'Neill, 1988). This pharmacology probably explains one report of the failure of paf antagonists to block implantation (Milligan and Finn, 1990).
The use of these paf antagonists within the dose range where they exerted contragestational actions in mice allowed judgements on targets of embryo-derived paf to be made. An embryo transfer model was used where either recipient females or the donors of embryos were treated with paf blocker. The treatment of embryo donors caused a reduction in implantation potential of embryos, while treatment of recipients had no effect on implantation rates following transfer (Spinks et al., 1990). This result infers, but does not explicitly show, that a primary target of paf was the embryo.
Further support for a direct action of paf on the embryo were the observations that the addition of paf to embryo culture media improved embryo development in vitro (Nishi et al., 1995; Roudebush et al., 1996; Stoddart et al., 1996, 2001; O'Neill 1997, 1998), enhanced rates of embryo metabolism (Ryan et al., 1989, 1990a, 1992), cell-cycle progression (Roberts et al., 1993) and improved rates of embryo implantation (O'Neill et al., 1989, 1992; Ryan et al., 1990b). All these effects of exogenously applied paf could be reversed by paf blockers. Furthermore, in the absence of exogenous paf, treatment of embryos in vitro with paf blockers (Emerson et al., 2000) or anti-paf antibodies (Roudebush et al., 1994) reduced their rate of development, and pafr–/– embryos had reduced rates of development in vitro (Lu et al., 2004). Taken together these results infer that a physiologically important target for embryo-derived paf is the embryo itself.
Current evidence shows that embryo-derived paf has many actions in early pregnancy. It clearly modifies oviduct function and seemingly creates beneficial changes to the embryo's milieu. Embryo-derived paf apparently may also promote embryo migration through the oviduct. It is assumed that these changes in the reproductive tract foster improved embryo development. An important target for embryo-derived paf, however, is the embryo-itself.
|
Embryo-derived paf's autocrine actions |
|---|
In an experimental model of reducing autocrine stimulation of development by embryo culture in limiting dilutions, it was shown that embryos have a requirement for exposure to diffusible autocrine trophic factors (including paf) over the first 48 h of development (to the late 2-cell stage). Deprivation of trophic support during this time resulted in a large increase in the proportion of embryos that underwent degeneration with a large proportion of cells undergoing apoptosis. Curiously, however, cell death did not occur until 24–48 h after the deprivation event occurred (primarily at the post-compaction stage of development). Supplementation of media with paf over this first 48 h of development could significantly reverse this embryopathy. Paf supplementation provided after the first 48 h of culture was not capable of rescuing the embryos (O'Neill, 1998
). The action of paf over the first couple of cell-cycles occurred without any apparent changes in the rate of cell-cycle progression (thus it did not act as a classical growth factor). It was concluded that the action of autocrine factors, such as paf, create a signal that is necessary for the subsequent survival of embryos past the 8-cell stage.
Treatment of 2-cell embryos with paf induces receptor-dependent characteristic [Ca2+]i transients (Roudebush et al., 1997; Emerson et al., 2000). Zygotes and 2-cell mouse embryos often display a spontaneous [Ca2+]i transient in vitro when embryos are collected and prepared in quantitative protein-free conditions and then exposed to medium containing albumin (Emerson et al., 2000). The spontaneous [Ca2+]i transients were a consequence of the action of embryo-derived paf. They were not seen in the absence of albumin and were blocked by a pafr-antagonist or by prior treatment of embryos with exogenous recombinant pafah. Reports of apparently normal preimplantation development in nominally protein-free media (Cholewa and Whitten, 1970) questions the importance of albumin-dependent paf release for embryo development. Yet such reports need to be viewed with caution. While the embryos are added to protein-free media, the embryos are collected from the reproductive tract with a considerable amount of contaminating protein (of which albumin is a significant component). Without very careful removal of all such contaminating protein, nominally protein-free culture media can actually contain protein concentrations in the low ug/ml range. This protein concentration is sufficient to support paf release in vitro.
Immediately following a [Ca2+]i transient induced by embryo-derived paf, embryos were not responsive to an subsequent challenge with exogenous paf. Inhibition of the transient induced by embryo-derived paf by treatment with pafah rendered the embryos sensitive to challenge with exogenous paf (Emerson et al., 2000). The resulting [Ca2+]i transients had similar characteristics to those induced by embryo-derived paf, including the presence of a refractory period after challenge.
The observation of [Ca2+]i transients induced by embryo-derived paf is evidence for the earliest physiological ligand-induced signal transduction event yet described in the embryo.
|
The action of paf on the zygote and 2-cell embryo |
|---|
Paf-induced [Ca2+]i transients were limited in the mouse embryo to the zygote and 2-cell stage (Emerson et al., 2000
). Yet functional studies had previously shown that exogenous paf also has trophic actions on the embryo at other stages of development (e.g. 8-cell and blastocyst) and these actions were apparently receptor-dependent (Ryan et al., 1990a, 1992; Roberts et al., 1993). This result suggests that paf may transduce its signal via different mechanisms at different stages of development. It may also mean that the consequence for the embryo of paf stimulation differs at different stages of development. Up to the 2-cell stage paf acts as a survival factor (O'Neill, 1998) and this seems to be mediated, at least in part by the mobilization of [Ca2+]i. In later stage embryos, paf exerts a trophic action that is not obviously mediated via [Ca2+]i mobilization. The mechanisms of signal transduction in the later preimplantation stages is currently not known. Thus, paf acts as a dual survival/trophic factor for the preimplantation embryo.
The paf-induced [Ca2+]i transients were mostly single transients across the embryo, that persisted for several minutes (Roudebush et al., 1997; Emerson et al., 2000). After the [Ca2+]i transient embryos were refractory to further paf challenges for an hour or more. After this time embryos spontaneously regained sensitivity to paf (Emerson et al., 2000). The periodic incidence of [Ca2+]i transients may therefore be regulated by both the rate of paf synthesis/release by the embryo and the rate at which the embryo becomes resensitized to paf. Such intermittent [Ca2+]i transients provide a hitherto unrecognized, information-rich, mechanism for signalling in the early embryo.
The response of the 2-cell embryo to exogenous paf was dose-dependent (dose range 0.037–370 nmol/l) and was inhibited by paf antagonists (Emerson et al., 2000). Embryos did not elicit a [Ca2+]i response to the inactive enantiomeric isomer of paf (3-o-alkyl-2-acetyl-sn-glycero-1-phosphocholine). Unfertilized oocytes and young zygotes (7–9 h after insemination) failed to show any [Ca2+]i transients in response to media containing albumin. By 10–13 h after insemination 25% of zygotes showed detectable [Ca2+]i transients in response to embryo-derived paf. For 2-cell embryos collected fresh from the reproductive tract, [Ca2+]i transients in response to embryo-derived paf varied with the age of the embryo. At 27–29 h after insemination there were modest responses to embryo-derived paf. By 31–33 h after insemination the average [Ca2+]i transient was significantly greater in peak amplitude and reached its peak earlier than observed at 27–29 h. At 35–37 h embryo responses to embryo-derived paf had declined in average amplitude and took longer to achieve peak amplitude. By 41–43 h the responses were significantly attenuated compared with each other time point tested for 2-cell embryos. No embryo-derived paf-induced [Ca2+]i transients were observed in 4-cell, 8-cell and morulae stage embryos. The lack of responsiveness in early zygotes and post 2-cell stage embryos was also evident after challenge with exogenous paf. This indicates that the failure to respond was not due to a deficiency in available embryo-derived paf but was due to embryos being incapable of responding at those stages of development (Emerson et al., 2000).
The [Ca2+]i transient appears to be a functionally significant consequence of paf action on the embryo since inhibition of its actions by buffering of the [Ca2+]i transients with BAPTA-AM [the Ca2+ chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetate-acetoxymethyl ester] blocked embryo development and this inhibition could be partially reversed by the addition of exogenous paf (Emerson et al., 2000).
The onset of responsiveness of embryos to paf required a transcriptional event inhibited by -amanitin (Emerson et al., 2000). These [Ca2+]i transients may be the earliest description of a functional response by the embryo that is dependent upon transcription from the zygotic genome. It will therefore be an important tool for investigating the regulatory processes controlling the onset of transcription from the zygotic genome.
|
Signal transduction by embryo-derived paf |
|---|
The paf-induced [Ca2+]i transient in 2-cell mouse embryos required the presence of both extracellular calcium and the release of internal calcium stores. The paf-induced [Ca2+]i transients were dependent on the release of inositol trisphosphate (IP3)-sensitive stores as assessed by its inhibition with U73122 [GenBank] (phospholipase C) and Xestospongin C and 2-APB (IP3 receptors) (Emerson et al., 2000
; Lu et al., 2003). [Ca2+]i transients were partially blocked by La3+ or Cd2+ suggesting an influx of calcium via cation channel(s) with at least partial ion selectivity. Three different classes of L-type calcium channel blockers significantly inhibited paf-induced signal transduction: benzothiazepine (diltiazem), phenylalkylamine (verapamil), and dihydropyridine (nifedipine and nimodipine). Inhibitors of T-type, P/Q-type, and N-type voltage-activated calcium channels and store-operated channels were without effect on paf-induced transients. Mn2+ quenching of Fura-2 showed that paf challenge of 2-cell embryos caused a rapid activation of cation influx that was inhibited by diltiazem (Emerson et al., 2000; Lu et al., 2003).
The voltage-gated Ca2+ channels consist of 1-subunits that form the ion-pore forming unit of the channel and regulatory 2
- and ß-subunits. The different functional subclasses of the channels are defined by the type of 1-subunit present. The major forms of L-type channels, each possess either an 1-C (cardiac, smooth muscle, neurons), 1-D (endocrine cells and neurons) or 1-S subunit (skeletal muscle). mRNA for the 1-C subunit (but not a1-D) was detected in 2-cell embryos. Indirect immunofluorescence also revealed expression of this protein in the membranes of 2-cell embryos. This result indicates that the Cav1.2 member of the L-type channel is present within the embryo. A L-type channel agonist (BAY K 8644) induced [Ca2+]i transients that were dependent upon extracellular calcium. BAY K 8644 and paf reciprocally desensitized responses to each other, inferring that they activate the same calcium channel. Stepwise membrane depolarization of the 2-cell embryo (by increasing the media concentration of KCl to 75 mmol/l) caused a [Ca2+]i transient that was blocked by treatment with diltiazem and verapamil. Whole-cell patch-clamp analysis detected a current that was activated by membrane depolarization. The current was maximal at a voltage of 36.94 ± 2.59 mV with a current of 0.23 ± 0.03 nA. Diltiazem, nifedipine and verapamil were equally effective in identifying this current activity. This current was inactivated by prior treatment of the embryo with paf (Lu et al., 2003), inferring that its action forms part of the paf-induced calcium signal.
These results show that 2-cell embryos possess a membrane cation channel activated by electrical depolarization. It has the properties of an L-type calcium channel. While the channel blockers used to identify the channels (diltiazem, verapamil, nifedipine and nimodipine) are highly selective inhibitors, it is noted that higher concentrations than normal were required to inhibit paf-induced [Ca2+]i transients in the 2-cell embryo (Lu et al., 2003). Thus, conclusive evidence of the identity of the paf-induced calcium influx channel is awaited.
Coupling between calcium influx and calcium release from internal stores is well recognized to occur in excitable cells (Bootman et al., 2001). The interdependence of calcium influx and store release in the early embryo may indicate a requirement for such coupling. This might be achieved by a paf-induced increases in [Ca2+]i that is localized to the vicinity of the calcium influx channel in response to paf. The inositol-triphosphate (IP3) receptor is known to be sensitized by calcium (Bootman et al., 2001), thus a localized increase in calcium due to influx may favour store release in response to paf-induced IP3 generation. The resulting release of internal IP3-sensitive stores of calcium might then sensitize neighbouring IP3 receptors, leading to a rapid release of [Ca2+]i stores and the generation of a substantive [Ca2+]i transient throughout the embryo.
Paf-induced calcium transients were dependent upon the expression of the known G-protein coupled pafr (Lu et al., 2004) and were inhibited by pertussis toxin (Lu et al., 2003). This infers that the receptor was coupled to the Gi protein in the 2-cell embryo (there was no apparent effect of Gs and the adenyl cyclase system on paf-induced calcium signalling) (Lu et al., 2004). Embryos that did not posses the pafr did not display normal paf-induced calcium transients (Lu et al., 2004). The absence of a functional pafr gene from embryos resulted in a decreased in the proportion of individual zygotes developing to the blastocyst stage in vitro (by 
35%), a decrease in the number of cells per embryo, and an increase in the proportion of cells in each blastocyst with fragmented nuclei.
Inhibitors of 1-o-phosphatidylinositol-3-kinase (PI3K) (LY294002 and wortmannin) blocked paf-induced [Ca2+]i transients (Lu et al., 2004). Selective inhibition of protein kinase C or tyrosine kinase was without obvious effect. Inhibition of PI3K blocked the paf-induced calcium influx into embryos and PI3K is known to activate L-type calcium channels in some cell types (Quignard et al., 2001). PI3K is also capable of activating phospholipase C
(Hiller and Sundler, 2002). RTPCR analysis shows that two-cell embryos expressed PI3K catalytic subunits p110, ß, and , and regulatory subunits p85 and ß. Furthermore, treatment of embryos in vitro with PI3K inhibitors reduced their viability (Lu et al., 2004). A summary of the likely pathways of paf-induced calcium signalling in the early embryo is shown in Figure 4.
|
Survival signalling
Deprivation of paf signalling in the early embryo leads to poor development and survival of preimplantation embryos. This has been demonstrated using various experimental techniques, including treatment of embryos with an anti-paf antibody (Roudebush et al., 1994), treatment with a range of pafr antagonists (Nishi et al., 1995; Emerson et al., 2000), deprivation of embryo-deprived paf by culturing in limiting dilutions (Stoddart et al., 1996; O'Neill, 1997, 1998) and the production and culture of embryos lacking the pafr gene (Lu et al., 2004). Deprivation of paf signalling causes a reduction in the proportion of embryos surviving to morphologically normal blastocysts, and where survival has occurred, the resulting blastocysts had fewer cells and more cells undergoing apoptosis (O'Neill, 1998; Lu et al., 2004). The addition of exogenous paf has been shown in several examples to be able to, at least partially, reverse the adverse effects of this deprivation (O'Neill, 1997, 1998).
Importantly, the PI3K signalling pathway(s) are common to many survival factors. The apparent redundancy of a range of the putative embryotrophic survival factors might be explained if their actions converge on PI3K. Downstream of PI3K are a number of important cell regulatory pathways that act to promote cell survival. It is beyond the scope of this paper to discuss these in detail (for reviews see Marte and Downward, 1997; Datta et al., 1999). Such mediators include, for example, the activation of Akt, CREB, NFkB, and the inactivation of Bad and p53. It is conceivable that different embryonic survival factors may exert differential effects on some of these pro-survival/anti-apoptotic factors. Such an outcome would provide a convenient basis for the apparent cooperativity of their actions.
It is interesting that in none of the models tested did paf deprivation cause complete inhibition of development. In the model of paf deprivation by limiting dilution, supplementation with any of several autocrine factors could significantly reverse the adverse effect (O'Neill, 1997). There is likely to be cooperation between several of a range of autocrine, paracrine and endocrine trophic factors in promoting the development of the early embryo (Paria and Dey, 1990; Lane and Gardner, 1992; Salahuddin et al., 1995; O'Neill, 1997). The survival of a significant number of embryos lacking the pafr suggests that a single trophic factor such as paf contributes approximately one-third of the trophic drive required for normal early embryo development in vitro (Lu et al., 2004). If it is assumed that each embryotrophic factor has a similar contribution to embryo viability as paf, then the actions of perhaps as few as three of these factors may be sufficient to support normal early embryo development. Given that there are many more than three trophic factors reported to act on the early embryo (Kane et al., 1997; Kaye, 1997; Hardy and Spanos, 2002), it is probable that loss of function of a number of these factors may be tolerated by the embryo providing that sufficient alternative trophic support is present.
|
The effects of assisted reproductive technologies on embryo-derived paf |
|---|
Assisted reproductive technology induces considerable variability in the release of paf by embryos. In an outbred mouse model, IVF and embryo culture caused a reduction in the release of paf from the embryo. There was an average 30-fold reduction in the release of paf from 2-cell embryos produced by IVF compared to equivalent embryos collected fresh from the reproductive tract (O'Neill, 1997
). By contrast, a study of an F1 mouse strain (B6D2) showed no effect of IVF on the amount of paf released (Ripps et al., 1993). In that investigation the amount of paf released was greater than observed in the outbred mice. Embryos from F1 strains typically show much greater vigour in culture and are not generally susceptible to the 2-cell block. The differences in the reported amounts of paf released by different strains of mice and the susceptibility of paf release to the stressors of culture may be one basis for their differing sensitivity to the adverse effects of assisted reproductive technology on embryo viability.
There is great variability in the amount of paf present in media conditioned by human IVF embryos. It is not possible to compare this with paf release from human embryos conceived in the reproductive tract. However, there are several reports of a positive association between the amount of paf released by human IVF embryos and their pregnancy potential following embryo transfer (O'Neill et al., 1985; Vereecken et al., 1990; Roudebush et al., 2002b). This association suggests that paf release in human embryos is commonly adversely affected by assisted reproductive technology. The amount of paf released was also related to embryo morphology, follicular maturation, and type of follicular stimulation (O'Neill et al., 1987; Nakatsuka et al., 1992). The cause of this reduced paf release following assisted reproductive technology is not clear. It was not apparently due to any deficiency in the paf biosynthetic machinery since a key rate-limiting enzyme (lysopaf acetyltransferase) is actually up-regulated following IVF in the mouse, and there is no reduction in the amount of paf associated with the embryo itself (O'Neill, 1997).
Clinical studies showed that supplementing human embryo culture media with synthetic paf resulted in a significant improvement in implantation and birth rates after embryo transfer (O'Neill et al., 1989, 1992). However, a multicentre study showed that this effect was inconsistent (O'Neill, 1993). The most likely reason for this is that synthetic paf is readily degraded by the pafah found in almost all heterologous protein sources, including serum and follicular fluid (O'Neill et al., 1989; Ammit and O'Neill, 1997a). Since such heterologous protein sources are a common component of culture media, a method of degradation or inhibition of pafah is required to achieve appropriate trophic actions of paf in vitro. In the absence of this inhibition of pafah, any paf added as a supplement is rapidly degraded and is thus unavailable. While pafah can be inactivated by acidification, the results are variable (Ammit and O'Neill, 1997a) and the implementation of this treatment within busy assisted reproductive technology laboratories has not found favour. Unlike synthetic paf added as a supplement, embryo-derived paf is released into a high-affinity binding site on albumin that protects it from degradation by pafah and extends its half-life to many hours in vitro (Ammit and O'Neill, 1997b). Thus, embryo-derived paf and synthetic paf are functionally different due to the unique nature of embryo-derived paf's binding to albumin. A research priority is the development of a means of artificially creating a formulation of paf in which it is bound to albumin in its protected configuration. Such a formulation offers the promise of a useful embryo culture media supplement. An alternative is the addition of synthetic paf to media that has a quantitative absence of pafah activity.
Paf is likely to be a suitable marker of embryo well-being after assisted reproductive technology. The exploitation of this potential has been limited by technical constraints, cost and the time required for quantitative paf assays. Quantitative measurement of paf involves a time-consuming and expensive liquid–liquid phospholipid extraction procedure, followed by partial purification by chromatography and then immunoassay. This requires a minimum 36 h to achieve a result. This generally means that results can only be used retrospectively. The liquid–liquid extraction system requires high skill and is unreliable in inexpert hands. Some studies have failed to detect the release of embryo-derived paf (Amiel et al., 1989; Smal et al., 1990). These reports either used unsuitable or no extraction procedures for recovery of embryo-derived paf, invalidating the assay results. The necessity for complex extraction procedures stems from the hydrophobic binding of embryo-derived paf to a specific site within albumin (Ammit and O'Neill, 1997b,c). The increasing use of assisted reproductive technology and the continued relatively poor viability of embryos so-produced make the availability of a suitable measure of embryo viability a high priority. Paf may well be a suitable candidate for this; it will, however, require a considerable investment to develop extraction and assay techniques that are sufficiently simple, reliable, quick and inexpensive for routine clinical use.
Some evidence indicates that paf signalling may be disrupted in embryos following assisted reproductive technology. It was shown in the mouse model that IVF also caused a marked delay in the onset of expression of mRNA for the pafr (Stojanov and O'Neill, 1999). Given the critical role for paf signalling in the 2-cell embryo (O'Neill, 1998; Emerson et al., 2000; Lu et al., 2004) this delay in the transcription of the receptor may have adverse consequences for paf signalling in the embryo, even should exogenous paf be provided as a supplement. It is noteworthy that analysis of early human IVF embryos by RT–PCR also failed to demonstrate pafr transcription in early embryos (Sharkey et al., 1995), although pafr expression was detected in human IVF blastocysts (Roudebush et al., 2003). In the pig it was found that IVF had no effect on pafr transcription, but that production of embryos by nuclear transfer did cause this expression to become highly variable and generally delayed (Lee et al., 2004). Supplementation of media with paf enhanced pafr gene expression and the rate of development of porcine embryos after nuclear transfer (Lee et al., 2004).
It was noted earlier that pafah I might also act to transduce paf's signal. It is therefore noteworthy that one study (Stojanov and O'Neill, 2001) found that expression of the pafah 1 subunit was delayed by several days when outbred mouse embryos were produced by IVF. There was no obvious effect of IVF or culture on the expression of pafah 1 2 transcripts. Given recent evidence for a role of differential pafah I subunit expression in the onset of apoptosis in some cells (Bonin et al., 2004), these epigenetic effects of IVF on pafah I expression may have developmental significance.
Assisted reproductive technology causes perturbation of the embryo's release of, and capacity to respond to, autocrine paf. The extent of this perturbation seems to vary between strains and individuals. Given the well-established role for this autocrine signalling pathway in the early embryo, this disruption is likely to have adverse consequences for the survival of embryos produced by assisted reproductive technology.
|
Conclusions |
|---|
Studies over the last 20 years have demonstrated that paf is a widely conserved trophic factor for the mammalian embryo. While its production has many consequences for maternal homeostasis, its autocrine actions on the embryo itself are of particular interest. The observation that this signalling system is perturbed by assisted reproductive technology provides an important tool for investigating the consequence of assisted reproductive technology.
The developing knowledge of the mode of paf's action reveals, possibly for the first time, robust principles for investigating and understanding the regulation of mammalian preimplantation embryo survival. As one of several potentially overlapping autocrine trophic factors acting on the early embryo, the increasingly detailed understanding of the mechanisms of action of paf should also provide insights into the mode of action of the whole class.
At the time of the discovery of embryo-derived paf, the early embryo was widely conceived as a rather quiescent organism, developing within the benign environment of the female reproductive tract and having little control over its own destiny. In the 20 years since, a considerable appreciation has developed of the manner in which the release of potent biological entities from the early embryo have profound effects in modulating the reproductive tract and also the embryo's own growth and survival.
|
Acknowledgements |
|---|
I thank the Australian NHMRC for project grant support for many of the studies reviewed here.
|
References |
|---|
Acker G, Hecquet F, Etienne A, Braquet P and Mencia-Huerta JM (1988) Role of platelet-activating factor (PAF) in the specific ovoimplantation in the rat: effect of the specific PAF-acether antagonist, BN 52021. Prostaglandins 35, 233–241.[CrossRef][Web of Science][Medline]
Ahmed A, Dearn S, Shams M, Li XF, Sangha RK, Rola-pleszczynski M and Jiang J (1998) Localization, quantification, and activation of platelet-activating factor receptor in human endometrium during the menstrual cycle: PAF stimulates NO, VEGF, and FAKpp125. FASEB J 12, 831–843.
Alecozay AA, Harper MJ, Schenken RS and Hanahan DJ (1991) Paracrine interactions between platelet-activating factor and prostaglandins in hormonally-treated human luteal phase endometrium in vitro. J Reprod Fertil 91, 301–312.
Amiel ML, Duquenne C, Benveniste J and Testart J (1989) Platelet aggregating activity in human embryo culture media free of PAF-acether. Hum Reprod 4, 327–330.
Ammit AJ and O'Neill C (1991) Comparison of a radioimmunoassay and bioassay for embryo-derived platelet-activating factor. Hum Reprod 6, 872–878.
Ammit AJ and O'Neill C (1997a) Optimization of a method for deactivation of platelet-activating factor:acetylhydrolase in serum for use in in-vitro fertilization culture media. Hum Reprod 12, 785–791.
Ammit AJ and O'Neill C (1997b) The role of albumin in the release of platelet-activating factor by mouse preimplantation embryos in vitro. J Reprod Fertil 109, 309–318.
Ammit AJ and O'Neill C (1997c) Studies of the nature of the binding by albumin of platelet-activating factor released from cells. J Biol Chem 272, 18772–18778.
Ammit AJ, Wells XE and O'Neill C (1992) Structural heterogeneity of platelet-activating factor produced by murine preimplantation embryos. Hum Reprod 7, 865–870.
Ando M, Suginami H and Matsuura S (1990a) Pregnancy suppression by a platelet activating factor anatgonist, ONO-6240, in mice. Asia-Oceania J Obstet Gynaecol 16, 169–174.
Ando M, Suginami H and Matsuura S (1990b) Pregnancy suppression by a structurally related antagonist for platelet activating factor, CV-6209, in mice. Asia-Oceania J Obstet Gynaecol 16, 283–290.
Angle MJ, Jones MA, McManus LM, Pinckard RN and Harper MJK (1988) Platelet-activating factor in the rabbit uterus during early pregnancy. J Reprod Fertil 83, 711–722.
Baldi E, Falsetti C, Krausz C, Gervasi G, Carloni V, Casano R and Forti G (1993) Stimulation of platelet-activating factor synthesis by progesterone and A23187 in human spermatozoa. Biochem J 292, 209–216.[Medline]
Baldi E, Bonaccorsi L, Finetti G, Luconi M, Muratori M, Susini T, Forti G, Serio M and Maggi M (1994) Platelet-activating Factor in human Endometrium. J Steriod Biochem Mol Biol 49, 359–363.[CrossRef][Web of Science][Medline]
Banks JB, Wykle RL, O'Flaherty JT and Lumb RH (1988) Evidence for protein-catalyzed transfer of platelet activating factor by macrophage cytosol. Biochim Biophys Acta 961, 48–52.[Medline]
Battye KM, Ammit AJ, O'Neill C and Evans G (1991) Production of platelet-activating factor by the preimplantation sheep embryo. J Reprod Fertil 93, 507–514.
Battye KM, Evans G and O'Neill C (1996) Ovine endometrium synthesizes and releases platelet-activating factor, which can cause the release of prostaglandin F2 alpha by the uterus in situ. Biol Reprod 54, 355–363.[Abstract]
Benveniste J, Henson PM and Cochrane CG (1972) Leukocyte-dependent histamine release from rabbit platelets. The role of IgE, basophils, and a platelet-activating factor. J Exp Med 136, 1356–1377.[Abstract]
Bonin F, Ryan SD, Migahed L, Mo F, Lallier J, Franks DJ, Arai H and Bennett SAL (2004) Anti-apoptotic actions of the platelet activating factor acetylhydrolase I alpha 2 catalytic subunit. J Biol Chem (in press, online), M410967200.
Bootman MD, Lipp P and Berridge M (2001) The organisation and functions of local Ca2+ signals. J Cell Sci 114, 2213–2222.[Web of Science][Medline]
Bratton DL, Clay KL and Henson PM (1991) A model for the extracellular release of PAF: the influence of plasma membrane phospholipid asymmetry. Biochim Biophys Acta 1062, 24–34.[Medline]
Brodersen R, Andersen S, Vorum H, Nielsen SU and Pedersen AO (1990) Multiple fatty acid binding to albumin in human blood plasma. Eur J Biochem 189, 343–349.[Web of Science][Medline]
Brown JR and Shockley P (1982) In Jost PC and Griffith OH (eds) Lipid-Protein Interactions. John Wiley & Sons, New York, pp 25–68.
Cahana A, Jin XL, Reiner O, Wynshaw-Boris A and O'Neill C (2003) A study of the nature of embryonic lethality in LIS1-/- mice. Mol Reprod Dev 66, 134–142.[CrossRef][Web of Science][Medline]
Chami O and O'Neill C (2001) Identification and regulation of the platelet-activating factor acetylhydrolase activity in the mouse uterus in early pregnancy. Reprod Fertil Dev 13, 367–376.[CrossRef][Medline]
Chami O, Megavand A, Ott TL, Bazer FW and O'Neill C (1999) Platelet-activating factor may act as an endogenous pulse-generator for ovine luteolytic PGF2 release. Am J Physiol 276, E782–E793.
Chami O, Evans G and O'Neill C (2004) Components of a platelet-activating factor-signaling loop are assembled in the ovine endometrium late in the estrous cycle. Am J Physiol Endocrinol Metab 287, E233–E240.
Cholewa JA and Whitten WK (1970) Development of two-cell mouse embryos in the absence of a fixed-nitrogen source. J Reprod Fertil 22, 553–555.
Collier M, O'Neill C, Ammit AJ and Saunders DM (1988) Biochemical and pharmacological characterisation of human embryo-derived platelet activating factor. Hum Reprod 3, 993–998.
Collier M, O'Neill C, Ammit AJ and Saunders DM (1990) Measurement of human embryo-derived platelet-activating factor (PAF) using a quantitative bioassay of platelet aggregation. Hum Reprod 5, 323–328.
Datta SR, Brunet A and Greenberg ME (1999) Cellular survival: a play in three Akts. Genes Dev 13, 2905–2927.
Demopoulos CA, Pinckard RN and Hanahan DJ (1979) Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem 254, 9355–9358.
Downing SJ, Chambers EL, Maguiness SD, Watson A and Leese HJ (1999) Effect of inflammatory mediators on the electrophysiology of the human oviduct. Biol Reprod 61, 657–664.
Downing S, Maguiness S, Tay J, Watson A and Leese H (2002) Effect of platelet-activating factor on the electrophysiology of the human Fallopian tube: early mediation of embryo-maternal dialogue? Reproduction 124, 523–529.[Abstract]
Emerson M, Travis AR, Bathgate R, Stojanov T, Cook DI, Harding E, Lu DP and O'Neill C (2000) Characterization and functional significance of calcium transients in the 2-cell mouse embryo induced by an autocrine growth factor. J Biol Chem 275, 21905–21913.
Ernest S and Bello-Reuss E (1999) Secretion of platelet-activating factor is mediated by MDR1 P-glycoprotein in cultured human mesangial cells. J Am Soc Nephrol 10, 2306–2313.
Fukuda A, Roudebush WE and Thatcher SS (1994) Platelet-activating factor enhances the acrosome reaction, fertilisation in vitro by subzonal sperm injection and resulting embryonic development in the rabbit. Hum Reprod 9, 94–99.
Gross TS, Thatcher WW and O'Neill C (1990) Platelet-activating factor alters the dynamics of prostaglandin and protein synthesis by endometrial explants from pregnant and cyclic cows at day 17 following estrus. Theriogenology 34, 205–218.[Medline]
Hardy K and Spanos S (2002) Growth factor expression and function in the human and mouse preimplantation embryo. J Endocrinol 172, 221–236.[Abstract]
Harvey A, Kind K and Thompson J (2002) REDOX regulation of early embryo development. Reproduction 123, 479–486.[Abstract]
Harvey MB and Kaye PL (1988) Insulin stimulates protein synthesis in compacted mouse embryos. Endocrinology 122, 1182–1184.
Hermoso M, Barrera N, Morales B, Perez S and Villalon M (2001) Platelet activating factor increases ciliary activity in the hamster oviduct through epithelial production of prostaglandin E2. Pflüg Archiv Eur J Physiol 442, 336–345.
Heyner S, Rao LV, Jarett L and Smith RM (1989) Preimplantation mouse embryos internalize maternal insulin via receptor-mediated endocytosis: pattern of uptake and functional correlations. Dev Biol 134, 48–58.[CrossRef][Web of Science][Medline]
Hiller G and Sundler R (2002) Regulation of phospholipase C-gamma 2 via phosphatidyl 3-kinase in macrophages. Cell Signlng 14, 169–173.
Hirotsune S, Fleck MW, Gambello MJ, Bix GJ, Chen A, Clark GD, Ledbetter D, McBain CJ and Wynshaw-Boris A (1998) Graded reduction of Pafah1b1 (Lis1) activity results in neuronal migration defects and early embryonic lethality. Nature Genet 19, 333–339.[CrossRef][Web of Science][Medline]
Ho YS, Swenson L et al. (1997) Brain acetylhydrolase that inactivates platelet-activating factor is a G-protein-like trimer. Nature 385, 89–93.[CrossRef][Medline]
Honda Z, Nakamura M et al. (1991) Cloning by functional expression of platelet-activating factor receptor from guinea pig lung. Nature 349, 342–346.[CrossRef][Medline]
Huang C, Mason JT, Stephenson FA and Levin IW (1986) Polymorphic phase behavior of platelet-activating factor. Biophys J 49, 587–595.[Medline]
Ishii S, Nagase T, Tashiro F, Ikuta K, Sato S, Waga I, Kume KM and Shimizu T (1997) Bronchial hyperreactivity, increased endotoxin lethality and melanocytic tumorigenesis in transgenic mice overexpressing platelet-activating factor receptor. EMBO J 16, 133–142.[CrossRef][Web of Science][Medline]
Ishii S, Kuwaki T et al. (1998) Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor. J Exp Med 187, 1779–1788.
Ishii S, Nagase T and Shimizu T (2002) Platelet-activating factor receptor. Prostagl Lipid Mediat 68-69, 599–609.
Kane MT, Morgan PM and Coonan C (1997) Peptide growth factors and preimplantation development. Hum Reprod Update 3, 137–157.
Kantar A, Giorgi G and Fiorini R (1991) Effect of PAF on erythrocyte membrane heterogeneity: a fluorescence study. Agents Act 32, 347–350.[CrossRef][Web of Science][Medline]
Kaye PL (1997) Preimplantation growth factor physiology. Rev Reprod 2, 121–127.[Abstract]
Kodama H, Muto H and Maki M (1989) Isolation and identification of embryo-derived platelet-activating factor in mice. Nippon Sanka Fujinka Gakkai Zasshi. [Acta Obstet Gynaecol Japonica] 41, 899–906.
Kojima T, Akagi S, Zeniya Y, Shimizu M and Tomizuka T (1996a) Evidence of platelet activation associated with establishment of pregnancy in cows with transferred embryos. J Dev 42, 225–235.
Kojima T, Zeniya Y and Ohshima K (1996b) Occurence of early pregnancy-associated thrombocytopenia in splenectomized rabbits. J Reprod Dev 42, 95–100.[CrossRef]
Kramp W, Pieroni G, Pinckard RN and Hanahan DJ (1984) Observations on the critical micellar concentration of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine and a series of its homologs and analogs. Chem Phys Lipids 35, 49–62.[CrossRef][Web of Science][Medline]
Kudolo GB and Harper MJ (1995) Lyso-PAF:acetyl-CoA acetyltransferase and CDP-choline cholinephosphotransferase activities in the rabbit endometrium. J Lipid Mediat Cell Sgnlng 11, 145–158.
Kumar R, Harper MJK and Hanahan DJ (1988) Occurrence of platelet-activating factor in rabbit spermatozoa. Archs Biochem Biophys 260, 497–502.[CrossRef][Web of Science][Medline]
Lane M and Gardner DK (1992) Effect of incubation volume and embryo density on the development and viability of mouse embryos in vitro. Hum Reprod 7, 558–562.
Lash GE and Legge M (2001) Localization and distribution of platelet activating factor receptors in the mouse ovary and oviduct during the estrous cycle and early pregnancy. Am J Reprod Immunol 45, 123–127.[Medline]
Lee SH, Kim DY et al. (2004) Role of messenger RNA expression of platelet-activating factor and its receptor in porcine in vitro-fertilized and cloned embryo development. Biol Reprod 71, 919–925.
Lu DP, Li Y, Bathgate R, Day M and O'Neill C (2003) Ligand-activated signal transduction in the 2-cell embryo. Biol Reprod 69, 106–116.
Lu DP, Chandrakanthan V, Cahana A, Ishii S and O'Neill C (2004) Trophic signals acting via phosphatidylinositol-3 kinase are required for normal pre-implantation mouse embryo development. J Cell Sci 117, 1567–1576.
Ludwig JC, Hoppens CL, McManus LM, Mott GE and Pinckard RN (1985) Modulation of platelet-activating factor (PAF) synthesis and release from human polymorphonuclear leukocytes (PMN): role of extracellular albumin. Archs Biochem Biophys 241, 337–347.[CrossRef][Web of Science][Medline]
Marte BM and Downward J (1997) PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem Sci 22, 355–358.[CrossRef][Web of Science][Medline]
Milligan SR and Finn CA (1990) Failure of platelet-activating factor (PAF-acether) to induce decidualisation in mice and failure of anatagonists of PAF to inhibit implanation. J Reprod Fertil 88, 105–112.
Minhas BS, Zhu Y, Kim H, Burwinkel TH, Ripps BA and Buster JE (1993) Embryonic platelet activating factor production in the rabbit increases during the preimplantation phase. J Assist Reprod Genet 10, 366–370.[CrossRef][Web of Science][Medline]
Morton H, Hegh V and Clunie GJA (1976) Studies of the rosette inhibition test in pregnant mice: evidence of immunosuppression? Proc R Soc Lond 193, 413–419.[Medline]
Nakatsuka M, Yoshida N and Kudo T (1992) Platelet activating factor in culture media as an indicator of human embryonic development after in-vitro fertilization. Hum Reprod 7, 1435–1439.
Nishi O, Tominaga T, Goto Y, Hayashi K and Mori T (1995) Effects of platelet activating factor on mouse embryo implantation in vitro. J Assist Reprod Genet 12, 330–334.[CrossRef][Web of Science][Medline]
Norris CJ, Peairs WA, Kudolo GB, Newton ER and Harper MJ (1994) Platelet-activating factor antagonists and implantation in rabbits. J Reprod Fertil 100, 395–401.
O'Neill C (1985a) Examination of the causes of early pregnancy associated thrombocytopenia in mice. J Reprod Fertil 73, 567–577.
O'Neill C (1985b) Partial characterisation of the embryo-derived platelet activating factor in mice. J Reprod Fertil 75, 375–380.
O'Neill C (1985c) Thrombocytopenia is a initial maternal response to fertilisation in mice. J Reprod Fertil 73, 559–566.
O'Neill C (1993) The actions of Platelet-activating factor (PAF) in the establishment of mammalian pregnancy. In Gianaroli L, Campana A, and Trounson AO (eds) Implantation in mammals. Raven Press, New York, pp 59–82.
O'Neill C (1995a) Activity of platelet-activating factor acetylhydrolase in the mouse uterus during the estrous cycle, throughout the preimplantation phase of pregnancy, and throughout the luteal phase of pseudopregnancy. Biol Reprod 52, 1995.
O'Neill C (1995b) Platelet-activating factor-antagonists reduce implantation in mice at low doses only. Reprod Fertil Dev 7, 51–57.[Medline]
O'Neill C (1997) Evidence for the requirement of autocrine growth factors for development of mouse preimplantation embryos in vitro. Biol Reprod 56, 229–237.[Abstract]
O'Neill C (1998) Autocrine mediators are required to act on the embryo by the 2-cell stage to promote normal development and survival of mouse preimplantation embryos in vitro. Biol Reprod 58, 1303–1309.
O'Neill C and Saunders DM (1984) Assessment of embryo quality. Lancet ii, 1035.
O'Neill C, Gidley-Baird AA, Pike IL, Porter RN, Sinosich MJ and Saunders DM (1985) Maternal blood platelet physiology and luteal phase endocrinology as a means of monitoring pre and post implantation embryo viability following in-vitro fertilisation. J In Vitro Fertil Embryo Transfer 2, 59–65.[CrossRef][Medline]
O'Neill C, Gidley-Baird AA, Pike IL and Saunders DM (1987) Use of a bio-assay for embryo-derived platelet activating factor as a means of assessing quality and pregnancy potential of human embryos. Fertil Steril 47, 969–975.[Web of Science][Medline]
O'Neill C, Collier MC and Saunders DM (1988) Embryo-derived platelet-activating factor: Its diagnostic and therapeutic future. Ann NY Acad Sci 541, 398–406.[Web of Science][Medline]
O'Neill C, Ryan JP, Collier M, Saunders DM, Ammit AJ and Pike IL (1989) Supplementation of IVF culture media with platelet activating factor (PAF) increased the pregnancy rate following embryo transfer. Lancet ii, 769–772.
O'Neill C, Ammit AJ, Korth R, Fleming S and Wells X (1991) The effect of inhibitors of platelet aggregation on the metabolism of platelet-activating factor (PAF) in washed rabbit platelets. Lipids 26, 1011–1014.[Web of Science][Medline]
O'Neill C, Ryan JP, Collier M, Saunders DM, Ammit AJ and Pike IL (1992) Outcome of pregnancies resulting from a trial of supplementing human IVF culture media with platelet-activating factor. Reprod Fertil Dev 4, 109–112.[CrossRef][Medline]
Orozco C, Perkins T and Clarke FM (1986) Platelet activating factor induces the expression of early pregnancy factor activity in female mice. J Reprod Fertil 78, 549–555.
Paria BC and Dey SK (1990) Preimplantation embryo development in vitro: Cooperative interactions among embryos and the role of growth factors. Proc Natl Acad Sci USA 87, 4756–4760.
Prescott SM, Zimmerman GA, Stafforini DM and McIntyre TM (2000) Platelet-activating factor and related lipid mediators. Annu Rev Biochem 69, 419–445.[CrossRef][Web of Science][Medline]
Quignard J-F, Mironneau J, Carricaburu V, Fournier B, Babich A, Nurnberg B, Mironneau C and Macrez N (2001) Phosphoinositide 3-kinase gamma mediates angiotensin ii-induced stimulation of l-type calcium channels in vascular myocytes. J Biol Chem 276, 32545–32551.
Raggers RJ, Vogels I and van Meer G (2001) Multidrug-resistance P-glycoprotein (MDR1) secretes platelet-activating factor. Biochem J 357, 859–865.[CrossRef][Web of Science][Medline]
Rappolee RA, Brenner CA, Schultz R, Mark D and Werb Z (1988) Developmental expression of PDGF, TGF- and TGF-ß genes in preimplantation mouse embryos. Science 241, 1823–1825.
Reiner O, Carozzo R, Shen Y, Wehnert M, Faustinella F, Dobyns WB, Caskey CT and Ledbetter DH (1993) Isolation of a Miller-Dieker lissencephaly gene containing G protein beta-subunit-like repeats. Nature 364, 717–721.[CrossRef][Medline]
Ripps BA, Zhu YP, Burwinkel TH, Kim HN, Buster JE and Minhas BS (1993) Platelet-activating factor production from in vitro and in vivo fertilized murine embryos is similar. Am J Reprod Immunol 30, 101–104.[Medline]
Roberts C, O'Neill C and Wright L (1993) Platelet activating factor (PAF) enhances mitosis in preimplantation mouse embryos. Reprod Fertil Dev 5, 271–279.[CrossRef][Medline]
Roudebush WE, Fukuda AI and Minhas BS (1993) Enhanced embryo development of rabbit oocytes fertilized in vitro with platelet activating factor (PAF)-treated spermatozoa. J Assist Reprod Genet 10, 91–94.[CrossRef][Web of Science][Medline]
Roudebush WE, Mathur S and Butler WJ (1994) Anti-platelet activating factor (PAF) antibody inhibits CFW mouse preimplantation embryo development. J Assist Reprod Genet 11, 414–418.[CrossRef][Web of Science][Medline]
Roudebush WE, Duralia DR and Butler WJ (1996) Effect of platelet-activating factor (PAF) on preimplantation mouse B6D2F1/J embryo formation. Am J Reprod Immunol 35, 272–276.[Medline]
Roudebush WE, LaMarche MD, Levine AS, Jiang H and Butler WJ (1997) Evidence for the presence of the platelet-activating factor receptor in the CFW mouse preimplantation two-cell-stage embryo. Biol Reprod 57, 575–579.[Abstract]
Roudebush WE, Purnell ET, Stoddart NR and Fleming SD (2002a) Embryonic platelet-activating factor: temporal expression of the ligand and receptor. J Assist Reprod Genet 19, 72–78.[CrossRef][Web of Science][Medline]
Roudebush WE, Wininger JD, Jones AE, Wright G, Toledo AA, Kort HI, Massey JB and Shapiro DB (2002b) Embryonic platelet-activating factor: an indicator of embryo viability. Hum Reprod 17, 1306–1310.
Roudebush WE, Massey JB, Kort HI, Elsner CW, Toledo AA and Shapiro DB (2003) Expression and presence of the platelet-activating factor receptor in human embryos. Fertil Steril 79, 1246–1248.[CrossRef][Web of Science][Medline]
Ryan JP, Spinks NR, O'Neill C, Ammit AJ and Wales RG (1989) Platelet activating factor (PAF) production by mouse embryos in-vitro and its effects on embryonic metabolism. J Cell Biochem 40, 387–395.[CrossRef][Web of Science][Medline]
Ryan JP, O'Neill C and Wales RG (1990a) Oxidative metabolism of energy substrates by preimplantation mouse embryos in the presence of platelet-activating factor. J Reprod Fertil 89, 301–307.
Ryan JP, Spinks NR, O'Neill C and Wales RG (1990b) Implantation potential and fetal viability of mouse embryos cultured in media supplemented with platelet activating factor. J Reprod Fertil 89, 309–315.
Ryan JP, O'Neill C, Ammit AJ and Roberts CG (1992) Metabolic and developmental responses of preimplantaion embryos to platelet activating factor. Reprod Fertil Dev 4, 387–398.[CrossRef][Medline]
Salahuddin S, Ookutsu S, Goto K, Nakanishi Y and Nagata Y (1995) Effects of embryo density and co-culture of unfertilized oocytes on embryonic development of in-vitro fertilized mouse embryos. Hum Reprod 10, 2382–2385.
Sharkey AM, Dellow K, Blayney M, Macnamee M, Charnock Jones S and Smith SK (1995) Stage-specific expression of cytokine and receptor messenger ribonucleic acids in human preimplantation embryos. Biol Reprod 53, 974–981.[Abstract]
Smal MA, Dziadek M, Cooney SJ, Attard M and Baldo BA (1990) Examination for platelet-activating factor production by preimplantation mouse embryos using a specific radioimmunoassay. J Reprod Fertil 90, 419–425.
Smith SK and Kelly RW (1988) Effect of platelet-activating factor on the release of PGF-2 by separated cells of human endometrium. J Reprod Fertil 82, 271–276.
Snyder F (1995) Platelet-activating factor: the biosynthetic and catabolic enzymes. Biochem J 305, 689–705.[Web of Science][Medline]
Spinks NR and O'Neill C (1988) Antagonists of embryo-derived platelet activating factor prevent implantation of mouse embryos. J Reprod Fertil 84, 89–98.
Spinks NR, Ryan JP and O'Neill C (1990) Antagonists of embryo-derived platelet activating factor act by inhibiting the ability of the mouse embryo to implant. J Reprod Fertil 88, 241–248.
Stein BA and O'Neill C (1994) Morphometric evidence of changes in the vasculature of the uterine tube of mice induced by the 2-cell embryo on the second day of pregnancy. J Anat 185, 397–403.[Medline]
Stewart AG and Phillips WA (1989) Intracellular platelet-activating factor regulates eicosanoid generation in guinea-pig resident peritoneal macrophages. Br J Pharmacol 98, 141–148.[Web of Science][Medline]
Stoddart NR, Wild AE and Fleming TP (1996) Stimulation of development in vitro by platelet-activating factor receptor ligands released by mouse preimplantation embryos. J Reprod Fertil 108, 47–53.
Stoddart NR, Roudebush WE and Fleming SD (2001) Exogenous platelet-activating factor stimulates cell proliferation in mouse pre-implantation embryos prior to the fourth cell cycle and shows isoform-specific stimulatory effects. Zygote 9, 261–268.[CrossRef][Web of Science][Medline]
Stojanov T and O'Neill C (1999) Ontogeny of expression of a receptor for platelet-activating factor in mouse preimplantation embryos and the effects of fertilisation and culure in vitro. Biol Reprod 60, 674–682.
Stojanov T and O'Neill C (2001) In vitro fertilization causes epigenetic modifications to the onset of gene expression from the zygotic genome in mice. Biol Reprod 64, 696–705.
Sueoka K, Dharmarajan AM, Miyazaki T, Atlas SJ and Wallach EE (1988) Platelet activating factor-induced early pregnacy factor activity from perfused rabbit ovary and oviduct. Am J Obstet Gynecol 159, 1580–1584.[Web of Science][Medline]
Suzuki H, Taguchi Y, Kojima T, Nishihira J and Kanagawa H (1995) Evidence for the production of platelet-activating factor by murine embryos and its putative role in the maternal physiology. Biochem Mol Biol Int 37, 617–626.[Web of Science][Medline]
Tiemann U, Neels P, Kuchenmeister U, Walzel H and Spitschak M (1996) Effect of ATP and platelet-activating factor on intracellular calcium concentrations of cultured oviductal cells from cows. J Reprod Fertil 108, 1–9.
Tiemann U, Tomek W, Schneider F, Wollenhaupt K, Kanitz W, Becker F, Pohland R and Alm H (2001a) Platelet-activating factor (PAF)-like activity, localization of PAF receptor (PAF-R) and PAF-acetylhydrolase (PAF-AH) activity in bovine endometrium at different stages of the estrous cycle and early pregnancy. Prostagl Lipid Mediat 65, 125–141.
Tiemann U, Viergutz T, Jonas L, Wollenhaupt K, Pohland R and Kanitz W (2001b) Fluorometric detection of platelet activating factor receptor in cultured oviductal epithelial and stromal cells and endometrial stromal cells from bovine at different stages of the oestrous cycle and early pregnancy. Domest Anim Endocrinol 20, 149–164.[CrossRef][Web of Science][Medline]
Tjoelker LW, Eberhardt C, Unger J, Trong HL, Zimmerman G, McIntyre TM, Stafforini DM, Prescott SM and Gray PW (1995) Plasma platelet-activating factor acetylhydrolase is a secreted phospholipase A2 with a catalytic triad. J Biol Chem 270, 25481–25487.
van den Bosch H, Schrakamp G, Hardeman D, Zomer AWM, Wanders RJA and Schutgens RBH (1993) Ether lipid synthesis and its deficiency in peroxisomal disorders. Biochimie 75, 183–189.[Medline]
Velasquez LA, Aguilera JG and Croxatto HB (1995) Possible role of platelet-activating factor in embryonic signalling during oviductal transport in the hamster. Biol Reprod 52, 1302–1306.[Abstract]
Velasquez LA, Maisey K, Fernandez R, Valdes D, Cardenas H, Imarai M, Delgado J, Aguilera J and Croxatto HB (2001) PAF receptor and PAF acetylhydrolase expression in the endosalpinx of the human Fallopian tube: possible role of embryo-derived PAF in the control of embryo transport to the uterus. Hum Reprod 16, 1583–1587.
Vereecken A, Delbeke L, Angle M, Gielis M, Gerris J, Johnston J and Buytaert P (1990) Embryo-derived platelet activating factor, a marker of embryo quality and viability following ovarian stimulation for in vitro fertilisation. J In Vitro Fertil Embryo Transfer 7, 321–326.[CrossRef][Web of Science][Medline]
Wales RG, Khurana NK, Edirisinghe WR and Pike IL (1985) Metabolism of glucose by preimplantation mouse embryos in the presence of glucagon, insulin, epinephrine, cAMP, theophylline and caffeine. Aust J Biol Sci 38, 421–428.[Medline]
Watanabe M, Aoki J, Manya H, Arai H and Inoue K (1998) Molecular cloning of cDNAs encoding alpha alpha2, and beta subunits of rat brain platelet-activating factor acetylhydrolase. Biochimica et Biophysica Acta 1401, 73–79.[Medline]
Wells XE and O'Neill C (1992) Biosynthesis of platelet-activating factor by the mouse two-embryo. J Reprod Fertil 96, 61–71.
Wells XE and O'Neill C (1994) Detection and preliminary characterization of two enzymes involved in biosynthesis of platelet-activating factor in mouse oocytes, zygotes and preimplantation embryos: dithiothreitol-insensitive cytidinediphospho-choline:1-o-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase and acetyl-coenzyme A:1-o-alkyl-2-lyso-sn-glycero-3-phosphocholine acetyltransferase. J Reprod Fertil 101, 385–391.
Wu C, Stojanov T, Chami O, Ishii S, Shimizu T, Li A and O'Neill C (2001) Evidence for the autocrine induction of capacitation of mammalian spermatozoa. J Biol Chem 276, 26962–26968.
Wykle RL, Malone B and Snyder F (1980) Enzymatic synthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine, a hypotensive and platelet-aggregating lipid. J Biol Chem 255, 10256–10260.
Yan W, Assadi AH, Wynshaw-Boris A, Eichele G, Matzuk MM and Clark GD (2003) Previously uncharacterized roles of platelet-activating factor acetylhydrolase 1b complex in mouse spermatogenesis. Proc Natl Acad Sci USA 100, 7189–7194.
Yasuda K, Satouchi K and Saito K (1986) Platelet-activating factor in normal rat uterus. Biochem Biophys Res Commun 138, 1231–1236.[CrossRef][Web of Science][Medline]
Yeung WSB, Chan YF, So WK, Ho PC and Chan STH (1992) Early pregnancy in human may not be associated with mild thrombocytopenia. J Assist Reprod Genet 9, 80–83.[CrossRef][Web of Science][Medline]
Zimmerman GA, Lorant DE, McIntyre TM and Prescott SM (1993) Juxtacrine intercellular signalling: another way to do it. Am J Respir Cell Mol Biol 9, 573–577.[Medline]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  X.L. Jin, V. Chandrakanthan, H.D. Morgan, and C. O'Neill Preimplantation Embryo Development in the Mouse Requires the Latency of TRP53 Expression, Which Is Induced by a Ligand-Activated PI3 Kinase/AKT/MDM2-Mediated Signaling Pathway (Reprinted with Correction) Biol Reprod, July 1, 2009; 81(1): 233 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.G. Katz-Jaffe, S. McReynolds, D.K. Gardner, and W.B. Schoolcraft The role of proteomics in defining the human embryonic secretome Mol. Hum. Reprod., May 1, 2009; 15(5): 271 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.L. Jin, V. Chandrakanthan, H.D. Morgan, and C. O'Neill Preimplantation Embryo Development in the Mouse Requires the Latency of TRP53 Expression, Which Is Induced by a Ligand-Activated PI3 Kinase/AKT/MDM2-Mediated Signaling Pathway Biol Reprod, February 1, 2009; 80(2): 286 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. O'Neill Phosphatidylinositol 3-kinase signaling in mammalian preimplantation embryo development Reproduction, August 1, 2008; 136(2): 147 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. O'Neill The potential roles for embryotrophic ligands in preimplantation embryo development Hum. Reprod. Update, May 1, 2008; 14(3): 275 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Harayama, H. Shindou, R. Ogasawara, A. Suwabe, and T. Shimizu Identification of a Novel Noninflammatory Biosynthetic Pathway of Platelet-activating Factor J. Biol. Chem., April 25, 2008; 283(17): 11097 - 11106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-K. Tse, Y.-L. Lee, W.-N. Chow, J. M. C. Luk, K.-F. Lee, and W. S. B. Yeung Preimplantation Embryos Cooperate with Oviductal Cells to Produce Embryotrophic Inactivated Complement-3b Endocrinology, March 1, 2008; 149(3): 1268 - 1276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, V. Chandrakanthan, M. L Day, and C. O'Neill Direct Evidence for the Action of Phosphatidylinositol (3,4,5)-Trisphosphate-Mediated Signal Transduction in the 2-Cell Mouse Embryo Biol Reprod, November 1, 2007; 77(5): 813 - 821. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||